高盛发表研究报告指，康龙化成(03759.HK) 第二季收入按年增长20.2%，主要受CDMO业务持续强劲带动，经调整净利润率由去年同期的12.2%及今年首季的11.4%提升至12.5%，其中CDMO及临床开发业务利润率分别达到26.8%及12.1%，按季比较均有提升，有助抵销实验室服务受汇率因素影响的利润率下跌。高盛指，康龙化成新项目订单势头维持强劲，总额按年增长30%，当中CDMO增长50%。...
Source Link高盛发表研究报告指，康龙化成(03759.HK) 第二季收入按年增长20.2%，主要受CDMO业务持续强劲带动，经调整净利润率由去年同期的12.2%及今年首季的11.4%提升至12.5%，其中CDMO及临床开发业务利润率分别达到26.8%及12.1%，按季比较均有提升，有助抵销实验室服务受汇率因素影响的利润率下跌。高盛指，康龙化成新项目订单势头维持强劲，总额按年增长30%，当中CDMO增长50%。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.